Hikma, a pharmaceutical company, completed the acquisition of Custopharm, a developer of complex sterile injectable generic products, from Water Street Healthcare Partners, a strategic partner and investor, for $425m. "This acquisition provides Hikma with an attractive opportunity to further strengthen our US injectables business, by adding an attractive and profitable portfolio of marketed products and an exciting pipeline of future opportunities. Custopharm is an accomplished operator in the US injectables market with a first-class scientific team and a strong regulatory track record. This acquisition is highly complementary to our existing business and adds high-quality and differentiated growth potential," Siggi Olafsson, Hikma CEO.